UBS Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,405,832
| Closed | -$36.4M | – | 11830 |
|
|
2022
Q3 | $36.4M | Buy |
2,405,832
+695,195
| +41% | +$8.08M | 0.02% | 881 |
|
|
2022
Q2 | $12.8M | Buy |
1,710,637
+100,781
| +6% | +$710K | 0.01% | 1632 |
|
|
2022
Q1 | $14.7M | Buy |
1,609,856
+1,602,984
| +23,326% | +$12.4M | ﹤0.01% | 1662 |
|
|
2021
Q4 | $48K | Buy |
6,872
+3,645
| +113% | +$38.1K | ﹤0.01% | 6954 |
|
|
2021
Q3 | $37K | Sell |
3,227
-53,288
| -94% | -$779K | ﹤0.01% | 6583 |
|
|
2021
Q2 | $905K | Buy |
56,515
+49,635
| +721% | +$851K | ﹤0.01% | 4261 |
|
|
2021
Q1 | $123K | Buy |
6,880
+2,189
| +47% | +$37.8K | ﹤0.01% | 5805 |
|
|
2020
Q4 | $63K | Sell |
4,691
-7,162
| -60% | -$86.5K | ﹤0.01% | 5988 |
|
|
2020
Q3 | $140K | Buy |
11,853
+4,287
| +57% | +$52.2K | ﹤0.01% | 4998 |
|
|
2020
Q2 | $111K | Sell |
7,566
-396,307
| -98% | -$5.86M | ﹤0.01% | 5220 |
|
|
2020
Q1 | $5.45M | Sell |
403,873
-72,684
| -15% | -$1.38M | ﹤0.01% | 1853 |
|
|
2019
Q4 | $11.5M | Buy |
+476,557
| New | +$9.87M | ﹤0.01% | 1828 |
|
|
2019
Q3 | – | Sell |
-1,000
| Closed | -$22.9K | – | 6778 |
|
|
2019
Q2 | $30K | Sell |
1,000
-752
| -43% | -$29K | ﹤0.01% | 6344 |
|
|
2019
Q1 | $84K | Sell |
1,752
-1,748
| -50% | -$76.9K | ﹤0.01% | 5202 |
|
|
2018
Q4 | $126K | Sell |
3,500
-4,661
| -57% | -$219K | ﹤0.01% | 5337 |
|
|
2018
Q3 | $502K | Sell |
8,161
-28,913
| -78% | -$1.86M | ﹤0.01% | 4401 |
|
|
2018
Q2 | $2.5M | Buy |
37,074
+27,665
| +294% | +$1.55M | ﹤0.01% | 2964 |
|
|
2018
Q1 | $511K | Buy |
9,409
+5,526
| +142% | +$309K | ﹤0.01% | 4184 |
|
|
2017
Q4 | $232K | Sell |
3,883
-36,005
| -90% | -$2.18M | ﹤0.01% | 4816 |
|
|
2017
Q3 | $1.94M | Buy |
39,888
+38,438
| +2,651% | +$2.1M | ﹤0.01% | 3152 |
|
|
2017
Q2 | $76K | Sell |
1,450
-1,073
| -43% | -$50K | ﹤0.01% | 5358 |
|
|
2017
Q1 | $114K | Sell |
2,523
-52
| -2% | -$2.32K | ﹤0.01% | 4998 |
|
|
2016
Q4 | $97K | Buy |
2,575
+492
| +24% | +$18.6K | ﹤0.01% | 5311 |
|
|
2016
Q3 | $78K | Buy |
2,083
+1,283
| +160% | +$28.3K | ﹤0.01% | 5153 |
|
|
2016
Q2 | $14K | Buy |
800
+500
| +167% | +$8.09K | ﹤0.01% | 6578 |
|
|
2016
Q1 | $4K | Sell |
300
-736
| -71% | -$11.6K | ﹤0.01% | 7117 |
|
|
2015
Q4 | $25K | Buy |
1,036
+236
| +30% | +$5.51K | ﹤0.01% | 6528 |
|
|
2015
Q3 | $14K | Sell |
800
-4,019
| -83% | -$72.8K | ﹤0.01% | 7038 |
|
|
2015
Q2 | $85K | Buy |
4,819
+4,019
| +502% | +$73.7K | ﹤0.01% | 5542 |
|
|
2015
Q1 | $25K | Sell |
800
-1,789
| -69% | -$51.9K | ﹤0.01% | 6753 |
|
|
2014
Q4 | $76K | Buy |
+2,589
| New | +$65.7K | ﹤0.01% | 5989 |
|
UBS Group's AERI Position: Q4 2022 in Review
UBS Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 2,405,832 shares — an estimated $36.4M sold.
UBS Group first reported a position in AERI in Q4 2014 and held it in 31 quarters. The position peaked at $36.4M in Q3 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- UBS Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- UBS Group sold 2,405,832 Aerie Pharmaceuticals shares in Q4 2022, an estimated $36.4M.
- UBS Group first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 31 quarters.
- UBS Group's Aerie Pharmaceuticals position peaked at $36.4M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.